CYCC
Closed
Cyclacel Pharmaceuticals Inc
0.3363
+0.0060 (+1.82%)
Last Update: 01 Jul 2025 23:23:00
Yesterday: 0.3303
Day's Range: 0.3175 - 0.3399
Send
sign up or login to leave a comment!
When Written:
0.5705
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for the treatment of cancer and other serious diseases. The company's lead product candidate is sapacitabine, which is being developed for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cyclacel is also developing other drug candidates, including seliciclib, CYC065, and CYC140, which target various types of cancer.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Cyclacel is publicly traded on the NASDAQ stock exchange under the ticker symbol CYCC. The company has collaborations with various academic and research institutions, including the University of Edinburgh, the University of Dundee, and the Medical University of South Carolina.
Cyclacel Pharmaceuticals Inc has a strong intellectual property portfolio, with over 200 patents and patent applications covering its drug candidates and related technologies. The company has received funding from various sources, including the National Cancer Institute, the European Union, and private investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Cyclacel is publicly traded on the NASDAQ stock exchange under the ticker symbol CYCC. The company has collaborations with various academic and research institutions, including the University of Edinburgh, the University of Dundee, and the Medical University of South Carolina.
Cyclacel Pharmaceuticals Inc has a strong intellectual property portfolio, with over 200 patents and patent applications covering its drug candidates and related technologies. The company has received funding from various sources, including the National Cancer Institute, the European Union, and private investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








